Healio

Most patients with advanced cancer do not undergo next-generation sequencing testing

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
ascopubs.org

Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing

Next-generation sequencing (NGS) is recommended for patients with metastatic prostate cancer (PC). Nationwide, testing rates are low. Whether PC disease characteristics and courses differ between ...
ascopubs.org

Barriers to and clinical outcomes with next-generation sequencing testing in metastatic prostate cancer.

Delays in time to first lenalidomide prescription fill for multiple myeloma. Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health ...
Medical Xpress

Deep-learning algorithms enhance mutation detection in cancer and RNA sequencing

Researchers from the Faculty of Engineering at The University of Hong Kong (HKU) have developed two innovative deep-learning algorithms, ClairS-TO and Clair3-RNA, that significantly advance genetic ...
RAPS

FDA drafts guidance on using next-generation sequencing to assess gene therapy safety

The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing (NGS) methods in nonclinical studies to assess the safety risks associated ...
GEN

The Throughput Paradox: Why Next-Generation Sequencing Bottlenecks Persist Beyond the Sequencer

The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue to witness sequencer throughput expansion with systems like the Illumina ...